Cafepharma Today

May 16 2025 - Novo CEO to depart as obesity drugmaker’s challenges rise
Novo CEO to depart as obesity drugmaker’s challenges rise
BioMarin expands enzyme expertise with $270M Inozyme buy
Amgen could owe Regeneron more than $400M after defeat in cholesterol drug antitrust suit
Eli Lilly collaborates with Rznomics on hearing loss treatment in $1.3 billion pact
*please scroll down for all the latest news *

Make it like cafepharma, but for different industries. Learn more about CompanyUnderground

Check open job listings in your area
Click here to stay updated on CP happenings

learn about pharmaceutical fraud
learn about the False Claims Act
learn about clinical lab fraud

Current News

submit a press release

This Week in Biotech
Motley Fool
Sunday, February 10, 2013 - 11:27am
tags:
Hyperion Therapeutics, Celgene Corporation, ONYX Pharmaceuticals, Oncolytics, Biogen Idec, Protalix BioTherapeutics, Pfizer
3 Humongous Health-Care Stocks This Week
Motley Fool
Sunday, February 10, 2013 - 11:22am
tags:
USANA Health Sciences, Neurocrine Biosciences, Dendreon
J&J President Visited Hip Surgeon Pre-Recall, Jury Told
Bloomberg
Saturday, February 9, 2013 - 12:08pm
tags:
JNJ, product recalls, hip recall, hip replacements
Can Johnson & Johnson Cash In on Stelara?
Motley Fool
Saturday, February 9, 2013 - 12:06pm
tags:
JNJ, Stelara, psoriasis, rheumatoid arthritis, Chron's Disease
Merck's Fight for Fat Profits
Motley Fool
Saturday, February 9, 2013 - 12:03pm
tags:
Merck
High-Quality Glaxo Could Still Have Something Left
Seeking Alpha
Saturday, February 9, 2013 - 12:03pm
tags:
GSK
Is There Any Upside Potential Left Here?
Motley Fool
Saturday, February 9, 2013 - 12:02pm
tags:
Keryx, Zerenex, hyperphosphatemia
Neurocrine Biosciences' CEO Discusses Q4 2012 Results - Earnings Call Transcript
Seeking Alpha
Saturday, February 9, 2013 - 12:01pm
tags:
Neurocrine Biosciences, earnings
Has Gilead Sciences Become the Perfect Stock?
Motley Fool
Saturday, February 9, 2013 - 10:54am
tags:
Gilead Sciences
3SBio to Go Private
Motley Fool
Saturday, February 9, 2013 - 10:53am
tags:
3SBio
Has GlaxoSmithKline Become the Perfect Stock?
Motley Fool
Saturday, February 9, 2013 - 10:52am
tags:
GSK
Onyx Pharmaceuticals Inc: Today's Featured Drugs Laggard
The Street
Saturday, February 9, 2013 - 10:52am
tags:
ONYX Pharmaceuticals
Celgene Corporation: Today's Featured Health Care Winner
The Street
Saturday, February 9, 2013 - 10:51am
tags:
Celgene Corporation
Gilead Sciences Inc: Today's Featured Drugs Winner
The Street
Saturday, February 9, 2013 - 10:50am
tags:
Gilead Sciences
Still Revving Up With Revlimid
Motley Fool
Saturday, February 9, 2013 - 10:49am
tags:
Revlimid, myelodysplastic syndrome, Multiple Myeloma, Celgene
Gilead Sciences completes acquisition of YM BioSciences
Yahoo/PR Newswire
Saturday, February 9, 2013 - 10:42am
tags:
Gilead Sciences, YM BioSciences, M&A
CEL-SCI Corporation Reports First Quarter 2013 Financial Results
Yahoo/BusinessWire
Saturday, February 9, 2013 - 10:41am
tags:
Cel-Sci, earnings
Analysis: Amgen fighting on both sides of the biosimilars battle
Fierce Biotech
Friday, February 8, 2013 - 12:05pm
tags:
Amgen, biosimilars
Biogen Idec: Solid Execution Trumps A Thinning Pipeline
Seeking Alpha
Friday, February 8, 2013 - 12:03pm
tags:
Biogen Idec
Pending Q4 Results: Dyax Partnerships Could Yield Sustained Growth For Investors
Seeking Alpha
Friday, February 8, 2013 - 12:03pm
tags:
Dyax

Pages

Latest CP Wire Articles

Hermes Intelligence Launches to Redefine Pharma Data Solutions [sponsored]
The Evolution of Medical Sales: What’s Changing in 2025?
FDA Scraps Key Vaccine Meetings—What It Means for Manufacturers
FDA approves Danziten, the first nilotinib treatment for Ph+ CML with no mealtime restrictions
Daily U.S. Flu Cases Expected to Nearly Double from Last Year by Late November, Predicts Novel Mathematical Forecasting Tool
PharmaBlock Receives 2024 ACS CMO Excellence in Green Chemistry Award, Marking a Second Consecutive Year of Recognition
Leading Clinical Research Network Centricity Research Acquires North Carolina-based Lucas Research
First-of-Its-Kind Alzheimer’s Disease Simulation Paves Way for Personalized Treatment: Penn State, Duke University Study
Centricity Research Appoints New CEO, CFO to Support Next Phase of Growth
Sermo Barometer Examines Influencers’ Impact on Patient Perceptions of Weight Loss Medications & Preventative Care Technologies

Latest Pharmagather Articles

Alzheimer's Update: Infectious Agents and Gamma-Secretase Too
In the Pipeline
Obesity Without Metabolic Dysfunction?
In the Pipeline
New Cell Therapy For Resistant Hodgkins Patients
In the Pipeline
Escape From the Lysosome
In the Pipeline
Heavy Water in Your NMR Experiments, And Elsewhere
In the Pipeline
GIPR: Agonists and Antagonists Do the Same Thing, But How
In the Pipeline
Mutant Proteins Classified
In the Pipeline
The Continuing Crisis, Part XIV: The Trumpist Worldview
In the Pipeline
Whole Lotta Snakin' Going On
In the Pipeline

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.